Table 1.

Glutamine metabolism‐related markers in relation to clinicopathological characteristics and EGFR mutation status. Glutamine transporter SLC1A5 and glutaminase GLS2 protein expression in adeno‐ versus squamous cell non‐small cell lung cancer

	Adenocarcinoma	Squamous cell carcinoma	P‐value
SLC1A5
<5%	19 (44.2%)	21 (60%)	P = 0.08
5–20%	11 (25.6%)	10 (28.6%)
>20%	13 (30.2%)	4 (11.4%)
GLS2
<5%	29 (67.4%)	31 (88.6%)	P = 0.019
5–20%	5 (11.6%)	3 (8.3%)
>20%	9 (20.9%)	1 (2.8%)

Two tissue samples were missing for adenocarcinomas and one sample was missing for squamous cell carcinomas, resulting in 43 adenocarcinomas and 35 squamous cell carcinomas for glutamine metabolism‐related marker analysis.

GLS2, glutaminase 2; SLC1A5, solute carrier family 1 (neutral amino acid transporter) member 5.